
1. world j gastroenterol. 2013 nov 7;19(41):6969-78. doi: 10.3748/wjg.v19.i41.6969.

pnpla3 i148m polymorphism progressive liver disease.

dongiovanni p(1), donati b, fares r, lombardi r, mancina rm, romeo s, valenti l.

author information: 
(1)paola dongiovanni, benedetta donati, roberta fares, rosa lombardi, luca
valenti, internal medicine, fondazione irccs ca' granda ospedale policlinico
milano, department pathophysiology transplantation, universit√† degli studi
di milano, 20122 milano, italy.

the 148 isoleucine methionine protein variant (i148m) patatin-like
phospholipase domain-containing 3 (pnpla3), protein expressed liver
and involved lipid metabolism, recently identified major
determinant liver fat content. several studies confirmed i148m
variant predisposes towards full spectrum liver damage associated with
fatty liver: simple steatosis steatohepatitis progressive fibrosis.
furthermore, i148m variant represents major determinant progression of
alcohol related steatohepatitis cirrhosis, influence fibrogenesis and
related clinical outcomes chronic hepatitis c virus hepatitis, possibly
chronic hepatitis b virus hepatitis, hereditary hemochromatosis primary
sclerosing cholangitis. all, studies suggest i148m polymorphism
may represent general modifier fibrogenesis liver diseases. remarkably,
the effect i148m variant fibrosis independent hepatic
steatosis inflammation, suggesting may affect quantity and
quality hepatic lipids biology non-parenchymal liver cells besides 
hepatocytes, directly promoting fibrogenesis. therefore, pnpla3 key player
in liver disease progression. assessment i148m polymorphism possibly 
inform clinical practice future, whereas determination effect
of 148m variant reveal mechanisms involved hepatic fibrogenesis.

doi: 10.3748/wjg.v19.i41.6969 
pmcid: pmc3819533
pmid: 24222941  [indexed medline]

